Publications

Publications

Scientific contributions highlighting the impact of Diatech Pharmacogenetics technologies in diagnostics.

Filter

All years 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008
All product lines Easy Easy PGX Helix Microsatelliti Myriapod Myriapod NGS Realquant Response
  • Easy

Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19

  • Response

Maria Letizia Lai., Thyroid cancer in Sardinian pediatric patients: report of 63 cases and a review of the literature

  • Easy PGX

A Promising Role of TGF-beta Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report

  • Easy PGX

Caterina De Luca et. al., RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer.

  • Myriapod

Conventional Transbronchial Needle Aspiration (cTBNA) and EBUS-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Retrospective Study on the Comparison of the Two Methods for Diagnostic Adequacy in Molecular Analysis

  • Easy

Comparison of Allplex™ SARS-CoV-2 Assay, Easy SARS-CoV-2 WE and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19

  • Easy, Myriapod

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

  • Myriapod

Correction to: Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction

  • Easy PGX

Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study

  • Response

Valentina Guarnieri et. al., PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.

Your next step starts here. Fill out the form and talk to us

Let's talk